Alan Kivitz
Impact in
- Rheumatology top 0.02%
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Osteoarthritis Treatment and Mechanisms
- Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research
Papers in
- Rheumatology 168
- Rheumatoid Arthritis Research and Therapies 97
- Spondyloarthritis Studies and Treatments 58
- Immunology 47
- Biosimilars and Bioanalytical Methods 18
- Psoriasis: Treatment and Pathogenesis 18
- Co-authors
- Désirée van der Heijde (19 shared papers)Philip J. Mease (22 shared papers)Stanley Cohen (24 shared papers)Jürgen Braun (9 shared papers)Francis X. Burch (5 shared papers)Maxime Dougados (10 shared papers)Roy Fleischmann (20 shared papers)Wayne Tsuji (4 shared papers)
- Journals
- Annals of the Rheumatic Diseases (66 papers)Rheumatology and Therapy (22 papers)Arthritis & Rheumatology (18 papers)Lara D. Veeken (16 papers)Clinical Therapeutics (8 papers)
- Partner nations
- United StatesGermanyUnited Kingdom
In The Last Decade
Alan Kivitz
258 papers receiving 12.6k citations
Alan Kivitz's Hit Papers
Peers
Comparison fields: 5 of 135
- Rheumatology 6.8k
- Hematology 1.8k
- Immunology 2.9k
- Orthopedics and Sports Medicine 916
- Pharmacology 1.3k
Countries citing papers authored by Alan Kivitz
This map shows the geographic impact of Alan Kivitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Kivitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Kivitz more than expected).
Fields of papers citing papers by Alan Kivitz
This network shows the impact of papers produced by Alan Kivitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Kivitz. The network helps show where Alan Kivitz may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan Kivitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 268 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Denosumab in Postmenopausal Women with Low Bone Mineral Density Hit paper breakdown → | 2006 | 893 |
| 2 | Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression Hit paper breakdown → | 2004 | 698 |
| 3 | Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial Hit paper breakdown → | 2006 | 665 |
| 4 | Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis Hit paper breakdown → | 1999 | 631 |
| 5 | Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial Hit paper breakdown → | 2003 | 586 |
| 6 | 2008 | 443 | |
| 7 | Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study Hit paper breakdown → | 2009 | 419 |
| 8 | Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial Hit paper breakdown → | 2018 | 299 |
| 9 | 2010 | 230 | |
| 10 | 2015 | 198 | |
| 11 | 2011 | 198 | |
| 12 | 2014 | 185 | |
| 13 | Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. | 2007 | 177 |
| 14 | Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial Hit paper breakdown → | 2021 | 173 |
| 15 | 2005 | 171 | |
| 16 | Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. | 2006 | 167 |
| 17 | 2017 | 166 | |
| 18 | Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. | 2007 | 155 |
| 19 | Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis Hit paper breakdown → | 2022 | 143 |
| 20 | 2013 | 141 |
About Alan Kivitz
Alan Kivitz is a scholar working on Rheumatology, Immunology, Hematology, Pharmacology and Genetics, having authored 268 papers that have together received 13.1k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (97 papers), Spondyloarthritis Studies and Treatments (58 papers), Inflammatory mediators and NSAID effects (23 papers), Chronic Lymphocytic Leukemia Research (22 papers), Autoimmune and Inflammatory Disorders Research (20 papers), Biosimilars and Bioanalytical Methods (18 papers), Psoriasis: Treatment and Pathogenesis (18 papers) and Monoclonal and Polyclonal Antibodies Research (16 papers). The work is most often cited by research in Rheumatology (6.8k citations), Hematology (1.8k citations), Immunology (2.9k citations), Orthopedics and Sports Medicine (916 citations) and Pharmacology (1.3k citations). Alan Kivitz has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Désirée van der Heijde, Philip J. Mease, Stanley Cohen, Jürgen Braun, Francis X. Burch, Maxime Dougados, Roy Fleischmann, Wayne Tsuji, John C. Davis and Mark C. Genovese. Their work appears in journals such as Annals of the Rheumatic Diseases, Rheumatology and Therapy, Arthritis & Rheumatology, Lara D. Veeken and Clinical Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.